Entero Therapeutics (ENTO) Competitors $0.49 -0.03 (-4.82%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.55%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends ENTO vs. CHRO, BTAI, PBM, APLM, BFRI, ENSC, AIMD, HOTH, NEUP, and INDPShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Chromocell Therapeutics (CHRO), BioXcel Therapeutics (BTAI), Psyence Biomedical (PBM), Apollomics (APLM), Biofrontera (BFRI), Ensysce Biosciences (ENSC), Ainos (AIMD), Hoth Therapeutics (HOTH), Neuphoria Therapeutics Inc. - Common Stock (NEUP), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Chromocell Therapeutics BioXcel Therapeutics Psyence Biomedical Apollomics Biofrontera Ensysce Biosciences Ainos Hoth Therapeutics Neuphoria Therapeutics Inc. - Common Stock Indaptus Therapeutics Entero Therapeutics (NASDAQ:ENTO) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in ENTO or CHRO? 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 0.5% of Entero Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate ENTO or CHRO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ENTO or CHRO? Chromocell Therapeutics received 1 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEntero TherapeuticsN/AN/AChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Which has better valuation & earnings, ENTO or CHRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$15.80MN/AN/AChromocell TherapeuticsN/AN/A-$7.38MN/AN/A Is ENTO or CHRO more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -87.06% -12.01% Chromocell Therapeutics N/A N/A -453.90% Does the media favor ENTO or CHRO? In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Chromocell Therapeutics'average media sentiment score. Company Overall Sentiment Entero Therapeutics Neutral Chromocell Therapeutics Neutral SummaryChromocell Therapeutics beats Entero Therapeutics on 7 of the 8 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / SalesN/A304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book0.216.717.644.63Net Income-$15.80M$138.11M$3.18B$245.69M7 Day Performance-4.10%-2.54%-1.95%-2.68%1 Month Performance-3.27%-2.00%-0.23%-2.16%1 Year PerformanceN/A-5.04%16.69%12.90% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.3276 of 5 stars$0.49-4.8%N/AN/A$2.46MN/A0.009Gap DownCHROChromocell TherapeuticsN/A$1.57+22.7%N/A-64.9%$9.52MN/A0.004BTAIBioXcel Therapeutics4.0733 of 5 stars$2.98+12.9%$37.00+1,141.6%-95.8%$9.26M$1.38M0.0090PBMPsyence BiomedicalN/A$1.26-7.7%N/A-97.0%$9.11MN/A0.00N/AAPLMApollomics2.4397 of 5 stars$7.46-10.7%$200.00+2,581.0%-89.7%$9.02M$1.22M0.0045Gap DownBFRIBiofrontera2.6469 of 5 stars$1.15flat$7.00+508.7%+13.6%$8.99M$34.07M0.0070News CoveragePositive NewsENSCEnsysce Biosciences0.224 of 5 stars$5.80-5.8%N/A-61.3%$8.36M$2.23M0.0010AIMDAinos0.4108 of 5 stars$0.59-4.4%N/A-23.5%$8.30M$120,000.000.0040Gap UpHOTHHoth Therapeutics2.8214 of 5 stars$1.08-6.9%$4.00+270.4%-21.5%$8.28MN/A-0.824Gap DownNEUPNeuphoria Therapeutics Inc. - Common Stock1.2883 of 5 stars$4.71+0.4%$21.00+345.9%N/A$8.21M$10,000.000.00N/AEarnings ReportINDPIndaptus Therapeutics3.1036 of 5 stars$0.83+4.6%$8.50+921.6%-52.9%$8.18MN/A0.006Gap Up Related Companies and Tools Related Companies Chromocell Therapeutics Competitors BioXcel Therapeutics Competitors Psyence Biomedical Competitors Apollomics Competitors Biofrontera Competitors Ensysce Biosciences Competitors Ainos Competitors Hoth Therapeutics Competitors Neuphoria Therapeutics Inc. - Common Stock Competitors Indaptus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts